Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as first-line systemic therapy for patients with non-small-cell lung cancer (nsclc) having mutations in the EGFR gene. Resistance to tkis eventually occurs in all nsclc patients treated with such drugs. In pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Oncol
Prif Awduron: Stockley, T., Souza, C.A., Cheema, P.K., Melosky, B., Kamel-Reid, S., Tsao, M.S., Spatz, A., Karsan, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Multimed Inc. 2018
Pynciau:
Practice Guideline
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927787/
https://ncbi.nlm.nih.gov/pubmed/29719432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4044
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg